Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce L Innis

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
Ebiomedicine|May 28, 2024
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoproteinCarly M Bliss, Raffael Nachbagauer, Chiara Mariottini, et al.
Vaccine|August 13, 2013
A model international partnership for community-based research on vaccine-preventable diseases: the Kamphaeng Phet-AFRIMS Virology Research Unit (KAVRU)Robert V Gibbons, Ananda Nisalak, In-Kyu Yoon, et al.
Human Vaccines & Immunotherapeutics|May 9, 2017
Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albuminAndrea A Berry, Remon Abu-Elyazeed, Clemente Diaz-Perez, et al.
The American Journal of Tropical Medicine and Hygiene|July 19, 2017
Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United StatesAlexander C Schmidt, Leyi Lin, Luis J Martinez, et al.
Immunohorizons|April 30, 2019
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in MiceAngela Choi, Badiaa Bouzya, Klaus-Daniel Cortés Franco, et al.
Open Forum Infectious Diseases|July 17, 2015
Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza DiseaseAnne Benoit, Jiri Beran, Jeanne-Marie Devaster, et al.
The Pediatric Infectious Disease Journal|May 25, 2012
Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of ageMark M Blatter, Nicola P Klein, Julie S Shepard, et al.
BMC Infectious Diseases|July 26, 2013
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 yearsDorothee Kieninger, Eric Sheldon, Wen-Yuan Lin, et al.
Vaccines|December 22, 2020
A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 VaccineWeina Sun, Stephen McCroskery, Wen-Chun Liu, et al.
Biorxiv : the Preprint Server for Biology|August 9, 2020
A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccineWeina Sun, Stephen McCroskery, Wen-Chun Liu, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
Ebiomedicine|May 28, 2024
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoproteinCarly M Bliss, Raffael Nachbagauer, Chiara Mariottini, et al.
Vaccine|August 13, 2013
A model international partnership for community-based research on vaccine-preventable diseases: the Kamphaeng Phet-AFRIMS Virology Research Unit (KAVRU)Robert V Gibbons, Ananda Nisalak, In-Kyu Yoon, et al.
Human Vaccines & Immunotherapeutics|May 9, 2017
Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albuminAndrea A Berry, Remon Abu-Elyazeed, Clemente Diaz-Perez, et al.
The American Journal of Tropical Medicine and Hygiene|July 19, 2017
Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United StatesAlexander C Schmidt, Leyi Lin, Luis J Martinez, et al.
Immunohorizons|April 30, 2019
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in MiceAngela Choi, Badiaa Bouzya, Klaus-Daniel Cortés Franco, et al.
Open Forum Infectious Diseases|July 17, 2015
Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza DiseaseAnne Benoit, Jiri Beran, Jeanne-Marie Devaster, et al.
The Pediatric Infectious Disease Journal|May 25, 2012
Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of ageMark M Blatter, Nicola P Klein, Julie S Shepard, et al.
BMC Infectious Diseases|July 26, 2013
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 yearsDorothee Kieninger, Eric Sheldon, Wen-Yuan Lin, et al.
Vaccines|December 22, 2020
A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 VaccineWeina Sun, Stephen McCroskery, Wen-Chun Liu, et al.
Biorxiv : the Preprint Server for Biology|August 9, 2020
A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccineWeina Sun, Stephen McCroskery, Wen-Chun Liu, et al.
Pageof 12